Biguanide (metformin) | Decrease hepatic glucose production Decrease intestinal glucose absorption Increase glucose uptake by skeletal muscle and fat
| Reduce blood glucose concentration Increase sensitivity to insulin Reduce blood lipid levels Oral administration
| |
Sulfonylureas | | | Hypoglycemia Weight gain Nausea Vomiting
|
Thiazolidinediones | Improve target cell response to insulin Decrease hepatic glucose output Increase insulin-dependent glucose uptake in skeletal muscle and fat
| Reduce blood glucose concentration Beneficial alteration of blood lipid levels Possible beneficial effects on pancreas and cardiovascular risk factors Oral administration
| |
Meglitinides and d-phenylalanine derivatives | | Reduce blood glucose concentration Reduce postprandial glucose excursions Stimulates insulin secretion Oral administration
| Hypoglycemia Diarrhea Weight gain
|
α-Glucosidase inhibitors | Inhibit pancreatic α-amylase and membrane-bound α-glucosidase enzymes Inhibit intestinal disaccharide metabolism, delaying glucose absorption
| Reduce blood glucose concentration Reduce postprandial glucose excursions Level out daytime glucose concentrations Disperse calories over time Weight neutral Oral administration
| |
Insulin and insulin analogues | | | |
Potential therapeutics discussed in this article | | | |
Incretin mimetics: Exenatide (others in clinical testing) | | Reduce blood glucose concentration Reduce postprandial glucose excursions Enhance glucose-dependent insulin secretion Suppress inappropriately elevated glucagon secretion Reduce food intake Slow gastric emptying Weight reduction or weight neutral Possible beneficial effects on pancreas (preclinical diabetes models) Subcutaneous injection
| |
DPP-IV inhibitors (clinical testing) | | Reduce blood glucose concentration Reduce postprandial glucose excursions Weight neutral Possible beneficial effects on pancreas and insulin sensitivity (preclinical diabetes models) Oral administration Status of disease progression may impact efficacy
| |